Harnessing free energy calculations for kinome-wide selectivity in drug discovery campaigns with a Wee1 case study.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 40858617.
- Also identified by DOI 10.1038/s41467-025-62722-w and PMC identifier 12381238.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Optimizing both on-target and off-target potencies is essential for developing effective and selective small-molecule therapeutics. Free energy calculations offer rapid potency predictions, usually within hours and with experimental accuracy and thus enables efficient identification of promising compounds for synthesis, accelerating early-stage drug discovery campaigns. While free energy predictions are routinely applied to individual proteins, here, we present a free energy framework for efficiently achieving kinome-wide selectivity that led to the discovery of selective Wee1 kinase inhibitors. Ligand-based relative binding free energy calculations rapidly identified multiple novel potent chemical scaffolds. Subsequent protein residue mutation free energy calculations that modified the Wee1 gatekeeper residue, significantly reduced their off-target liabilities across the kinome. Thus, with judicious use of this gatekeeper residue selectivity handle, applying this computational strategy streamlined the optimization of both on-target and off-target potencies, offering a roadmap to expedite drug discovery timelines by decreasing unanticipated off-target toxicities.
Medical subject headings
- Protein-Tyrosine Kinases
- Drug Discovery
- Cell Cycle Proteins
- Protein Kinase Inhibitors
- Nuclear Proteins